Pregled bibliografske jedinice broj: 1133400
Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact
Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact // Neuroscience & Biobehavioral Reviews, 127 (2021), 958-978 doi:10.1016/j.neubiorev.2021.06.027 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1133400 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Interplay between immunity and amyotrophic lateral sclerosis:
Clinical impact
Autori
De Marchi, Fabiola ; Munitic, Ivana ; Amedei, Amedeo ; Berry, James D. ; Feldman, Eva L. ; Aronica, Eleonora ; Nardo, Giovanni ; Van Weehaeghe, Donatienne ; Niccolai, Elena ; Prtenjaca, Nikolina ; Sakowski, Stacey A. ; Bendotti, Caterina ; Mazzini, Letizia
Izvornik
Neuroscience & Biobehavioral Reviews (0149-7634) 127
(2021);
958-978
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
amyotrophic lateral sclerosis ; biomarkers ; immunity ; inflammation ; target ; targeted therapies.
Sažetak
Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative disease. Despite decades of research and many new insights into disease biology over the 150 years since the disease was first described, causative pathogenic mechanisms in ALS remain poorly understood, especially in sporadic cases. Our understanding of the role of the immune system in ALS pathophysiology, however, is rapidly expanding. The aim of this manuscript is to summarize the recent advances regarding the immune system involvement in ALS, with particular attention to clinical translation. We focus on the potential pathophysiologic mechanism of the immune system in ALS, discussing local and systemic factors (blood, cerebrospinal fluid, and microbiota) that influence ALS onset and progression in animal models and people. We also explore the potential of Positron Emission Tomography to detect neuroinflammation in vivo, and discuss ongoing clinical trials of therapies targeting the immune system. With validation in human patients, new evidence in this emerging field will serve to identify novel therapeutic targets and provide realistic hope for personalized treatment strategies.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Projekti:
HRZZ-IP-2018-01-8563 - Kontrola neurodegeneracije moduliranjem sprege između upale i proteinopatije (ImmunoModifyCNS) (Munitić, Ivana, HRZZ - 2018-01) ( CroRIS)
Ustanove:
Sveučilište u Rijeci - Odjel za biotehnologiju
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE